Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15617596 | 0.94 | ACP3 (0.58) | ABCB11CYP2C9ACP3GPR88L3MBTL1 | |
| SCHEMBL3941057 | 0.90 | ABCB11 (0.49) | ABCB11CA1CA2TSHRCYP2C9 | |
| SCHEMBL19984896 | 0.90 | TDP1 (0.51) | ABCB11CA1CA2TSHRCYP2C9 | |
| SCHEMBL11351348 | 0.82 | CA1 (0.50) | CA1CA2TSHRCA12CA7 | |
| SCHEMBL9711999 | 0.82 | ABCB11 (0.52) | ABCB11CA1CA2TSHRCYP2C9 | |
| SCHEMBL7610044 | 0.81 | KIF11 (0.49) | ABCB11TSHRCYP2C9CYP17A1AOC3 | |
| SCHEMBL4447091 | 0.80 | ABCB11 (0.47) | ABCB11TSHRCYP2C9CYP17A1ACP3 | |
| SCHEMBL4372787 | 0.80 | AOC3 (0.61) | ABCB11CA1CA2TSHRCYP2C9 | |
| SCHEMBL7419755 | 0.80 | ABCB11 (0.70) | ABCB11CA1CA2TSHRCYP2C9 | |
| SCHEMBL17660055 | 0.80 | AOC3 (0.61) | ABCB11CA1CA2TSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109456161-A | A kind of method of visible light catalytic oxidation fracture carbon-carbon bond | 中国科学院大连化学物理研究所 | 2019-03-12 | — | — | CN | claimed |
| CN-109456160-A | A kind of method of photochemical catalytic oxidation fracture lignin model compound | 中国科学院大连化学物理研究所 | 2019-03-12 | — | — | CN | claimed |
| CN-109456161-A | A kind of method of visible light catalytic oxidation fracture carbon-carbon bond | 中国科学院大连化学物理研究所 | 2019-03-12 | — | — | CN | disclosed |
| EP-2306986-B1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1317461-A1 | 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES | SCHERING CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022623-A1 | 4-CYCLOHEXYL-1,3,2-OXAZABOROLIDINE CHIRAL ACCESSORIES | SCHERING CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0859770-A4 | — | — | 1998-10-07 | — | — | EP | disclosed |
| EP-0859770-A1 | PROCESS FOR THE SYNTHESIS OF BENZO b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1996040676-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | ABCB11 2/4885CA1 620/4885CA2 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.